PRIMARY STUDY
A New Clinical Utility for Tubular Markers to Identify Kidney Responders to Saxagliptin Treatment in Adults With Diabetic Nephropathy
Key Findings: In the group receiving saxagliptin as add-on therapy for diabetic kidney disease. levels of liver-type fatty acid-binding protein (uL-FABP) were higher, but not significantly
Type of Study: Clinical Trial
Study Sample Size: 80
Study Result: Inconclusive
Research Location(s): Egypt
Year of Pub: 2021
Cannabinoids Studied: Fatty Acid-Binding Protein (FABP)
Phytocannabinoid Source: Not Applicable
Citation: Mohsen M, et al. A New Clinical Utility for Tubular Markers to Identify Kidney Responders to Saxagliptin Treatment in Adults With Diabetic Nephropathy. Can J Diabetes. 2022; 46:134-141.e2. doi: 10.1016/j.jcjd.2021.07.004
Authors: Mohsen M, Elberry AA, Rabea AM, Khalil DM, Abdelrahim MEA, Hussein RRS
